(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 617MM | -0% |
Gross Profit | 189.8MM | -18% |
Cost Of Revenue | 427.2MM | +10% |
Operating Income | 14.2MM | -81% |
Operating Expenses | 175.6MM | - |
Net Income | -101.4MM | -753% |
R&D | 46.1MM | +11% |
G&A | 109MM | -4% |
Amortization | 40.7MM | +0% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
BRIDGEWATER, N.J., March 25, 2024--Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
Despite Revenue Growth, Company Faces GAAP Net Loss and Provides 2024 Guidance
BRIDGEWATER, N.J., March 01, 2024--Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced its results for the fourth quarter and full year ended December 31, 2023.
BRIDGEWATER, N.J. & CADEMPINO, Switzerland, February 27, 2024--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) ("Amneal" or the "Company") today announced that it has entered into an exclusive licensing agreement with Zambon Biotech SA, part of the Zambon group ("Zambon"), for IPX203 in the European Union, United Kingdom, and Switzerland.
Key Insights Amneal Pharmaceuticals' significant insider ownership suggests inherent interests in company's expansion...
BRIDGEWATER, N.J., February 13, 2024--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that Chirag Patel, Co-Chief Executive Officer, will participate in the following investor conference.
BRIDGEWATER, N.J., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”) today announced that it has provided a Complete Response resubmission to the U.S. Food and Drug Administration (FDA) for IPX203, a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules for the treatment of Parkinson’s disease (PD). The original NDA for IPX203 resulted in a Complete Response Letter (CRL) from FDA. The resubmission package included
BRIDGEWATER, N.J., January 31, 2024--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) announced today that the Company will release its fourth quarter and full year 2023 financial results on Friday, March 1, 2024, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time.
MONTREAL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive license agreement with Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal"), granting Knight the exclusive rights to seek regulatory approval and commercialize IPX203 in Canada and Latin America. IPX203 is a novel, oral formulation of carbidopa/levodopa (CD/LD) extended-release capsules design
BRIDGEWATER, N.J., January 10, 2024--Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) ("Amneal" or the "Company") today announced the approval and launch of fluorometholone ophthalmic suspension. The product received 180-day competitive generic therapy (CGT) exclusivity from the U.S. Food and Drug Administration, a status that applies to first-marketed generics of key medicines.